| Vaccine-Based Immunotherapy Regimen For NSCLC and TNBC (NCT03674827) | Pfizer | 2018-11-27 |
| Vapor Ablation for Localized Cancer Lesions of the Lung (VAPORIZE) (NCT03198468) | Uptake Medical Technology, Inc. | 2018-11-21 |
| MGC018 With or Without MGA012 in Advanced Solid Tumors (NCT03729596) | MacroGenics | 2018-11-21 |
| Integrated Discovery of New Immuno-Molecular Actionable Biomarkers for Tumors With Immune-suppressed Environment (NCT03706625) | Assistance Publique - Hôpitaux de Paris | 2018-11-20 |
| Anlotinib Plus Sintilimab for NSCLC Patients With First-generation EGFR-TKIs Drug Resistance Along With T790M Negative (NCT03765775) | First Hospital of Shijiazhuang City | 2018-11-20 |
| A First-in-Human Study of JAB-3068 (SHP2 Inhibitor) in Adult Patients With Advanced Solid Tumors in China (NCT03565003) | Jacobio Pharmaceuticals Co., Ltd. | 2018-11-20 |
| A Phase 2 Study Adding Ascorbate to Chemotherapy and Radiation Therapy for NSCLC (NCT02905591) | Joseph J. Cullen, MD, FACS | 2018-11-16 |
| Afatinib on CNS Metastases and LMD in EGFR Mutation Positive NSCLC (NCT03711422) | National Cancer Centre, Singapore | 2018-11-16 |
| Anlotinib Combined With Docetaxel for Advanced Non-Small Cell Lung Cancer（ALTER-L034） (NCT03735264) | The Affiliated Hospital of Qingdao University | 2018-11-15 |
| PDX Models From EGFR Mutant Tumors (NCT03872440) | Addario Lung Cancer Medical Institute | 2018-11-14 |
| Circulating Tumor DNA Longitudinal Monitoring in Stage III-IV Lung Cancer Patients (NCT03664843) | First Hospital of Shijiazhuang City | 2018-11-09 |
| Study of ADCT-301 in Patients With Selected Advanced Solid Tumors (NCT03621982) | ADC Therapeutics S.A. | 2018-11-09 |
| A Study of Anlotinib in Combination With Docetaxel Versus Docetaxel Alone in Participants With Advanced NSCLC (NCT03732001) | China Medical University, China | 2018-11-08 |
| ALEctinib for the Treatment of Pretreated RET-rearranged Advanced Non-small Cell Lung Cancer (NCT03445000) | ETOP IBCSG Partners Foundation | 2018-11-06 |
| Fasting-mimicking Diet With Chemo-immunotherapy in Non-small Cell Lung Cancer (NSCLC) (NCT03700437) | Indiana University | 2018-11-02 |
| Pharmacogenetics in Non Small Cell Lung Cancer (NCT03791151) | Ain Shams University | 2018-11-01 |
| Anlotinib Hydrochloride as Second-line Therapy in Elderly Patients With EGFR Wild-type Lung Adenocarcinoma (NCT03728374) | First Affiliated Hospital of Wenzhou Medical University | 2018-11-01 |
| Evaluating the Safety and Efficacy of Pembrolizumab Combined With MWA for Advanced NSCLC (NCT03769129) | Second Affiliated Hospital of Guangzhou Medical University | 2018-11-01 |
| Biomarkers of Response to Pembrolizumab Combined With Chemotherapy in Non-Small Cell Lung Cancer (KEYNOTE-782, MK-3475-782) (NCT03664024) | Merck Sharp & Dohme LLC | 2018-10-30 |
| First Line Treatment in EGFR Mutation Positive Advanced NSCLC Patients With Central Nervous System (CNS) Metastases (NCT03653546) | Alpha Biopharma (Jiangsu) Co., Ltd. | 2018-10-29 |
| Osimertinib With Stereotactic Radiosurgery (SRS) in Brain Metastases From EGFR Positive NSCLC (NCT03535363) | Case Comprehensive Cancer Center | 2018-10-26 |
| Open-label PET Study With [11C]Osimertinib in Patients With EGFRm NSCLC and Brain Metastases (NCT03463525) | AstraZeneca | 2018-10-24 |
| Daily vs. Non-Daily SBRT for NSCLC (NCT03624907) | University of Florida | 2018-10-19 |
| A Trial of Pembrolizumab in Combination With Chemotherapy and Radiotherapy in Stage III NSCLC (KEYNOTE-799, MK-3475-799) (NCT03631784) | Merck Sharp & Dohme LLC | 2018-10-19 |
| Study of Alkotinib in Patients With Advanced Non Small Cell Lung Cancer (NCT03607188) | Suzhou Zelgen Biopharmaceuticals Co.,Ltd | 2018-10-18 |
| Anlotinib Plus Docetaxel for the Treatment of EGFR Wild-type Advanced Non-small-cell Lung Cancer (NCT03624309) | Hunan Cancer Hospital | 2018-10-15 |
| Trial of Photodynamic Therapy Versus Argon Plasma Coagulation for Lung Cancer With Endobronchial Obstruction (NCT03564054) | University of Florida | 2018-10-11 |
| Study of Telisotuzumab Vedotin (ABBV-399) in Participants With Previously Treated c-Met+ Non-Small Cell Lung Cancer (NCT03539536) | AbbVie | 2018-10-10 |
| Pharmacokinetically-guided on the Individualization of Pembrolizumab Administration in the Treatment of Lung Cancer (NCT05226728) | Sun Yat-sen University | 2018-10-10 |
| Trial of Trametinib and Ponatinib in Patients With KRAS Mutant Advanced Non-Small Cell Lung Cancer (NCT03704688) | Memorial Sloan Kettering Cancer Center | 2018-10-09 |
| Quality of Life and Physical Fitness After Immune Checkpoint Inhibitors (NCT03946007) | University Medical Center Groningen | 2018-10-04 |
| A Study of Participants in Australia Who Have Non-small Cell Lung Cancer Being Treated With Nivolumab (NCT03804554) | Bristol-Myers Squibb | 2018-10-03 |
| Phase II Clinical Trial of NIVO-IPI-TAXANE in Untreated Metastatic NSCLC (NCT03573947) | Jeffrey Clarke | 2018-10-02 |
| M7824 Versus Pembrolizumab as a First-line (1L) Treatment in Participants With Programmed Death-ligand 1 (PD-L1) Expressing Advanced Non-small Cell Lung Cancer (NSCLC) (NCT03631706) | EMD Serono Research & Development Institute, Inc. | 2018-10-01 |
| PD-L1 Imaging in Non Small Cell Lung Cancer' (PINNACLE) (NCT03514719) | Radboud University Medical Center | 2018-10-01 |
| Anlotinib Plus Docetaxel for the Treatment of EGFR/ALK/ROS1 Mutation-negative Advanced Nonsquamous NSCLC (NCT03654027) | First Affiliated Hospital of Guangxi Medical University | 2018-10-01 |
| Hypofractionated Radiotherapy With Carboplatin and Paclitaxel in Non-Small Cell Lung Cancer (NCT03699033) | Stephanie Smiddy | 2018-10-01 |
| Epidermal Growth Factor Receptor (EGFR) T790M Mutation Testing Practices in Hong Kong (NCT03519958) | AstraZeneca | 2018-09-30 |
| CCCR-NK92 Cells Immunotherapy for Non-small Cell Lung Carcinoma (NCT03656705) | Henan Medical University | 2018-09-29 |
| Exemestane in Post-Menopausal Women With NSCLC (NCT02666105) | Masonic Cancer Center, University of Minnesota | 2018-09-27 |
| A Study of RC48-ADC in Subjects With Advanced Non-small Cell Lung Cancer (NCT04311034) | RemeGen Co., Ltd. | 2018-09-26 |
| A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies (NCT03652077) | Incyte Corporation | 2018-09-24 |
| DS-1205c With Gefitinib for Metastatic or Unresectable Epidermal Growth Factor Receptor (EGFR)-Mutant Non-Small Cell Lung Cancer (NCT03599518) | Daiichi Sankyo Co., Ltd. | 2018-09-21 |
| CABozantinib in Non-Small Cell Lung Cancer (NSCLC) Patients With MET Deregulation (NCT03911193) | Fondazione Ricerca Traslazionale | 2018-09-21 |
| Assessment of Precision Irradiation in Early NSCLC and Interstitial Lung Disease (NCT03485378) | London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's | 2018-09-20 |
| Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer (NCT03412877) | National Cancer Institute (NCI) | 2018-09-06 |
| Study of Efficacy and Safety of Dabrafenib and Trametinib Combination Therapy in Japanese Patients With BRAF V600E Stage IV NSCLC (NCT02672358) | Novartis Pharmaceuticals | 2018-09-03 |
| Expressiona and Diagnostic Potential of miRNAs in NSCLC (NCT05815407) | Al-Azhar University | 2018-09-01 |
| Cardiopulmonary Toxicity of Thoracic Radiotherapy (NCT03978377) | University Medical Center Groningen | 2018-09-01 |
| An Autologous NK/CIK Cell Product (PB101) in Combination With EGFR-TKI for Treating Lung Cancer (NCT07271446) | Precision Biotech Taiwan Corp. | 2018-09-01 |
| Clinical Evaluation of Genetron Lung Cancer Panel in Non-small Cell Lung Cancer Patients (NCT05023746) | Genetron Health | 2018-08-30 |
| Safety, Tolerability, Immunogenicity, and Antitumor Activity of GEN-009 Adjuvanted Vaccine (NCT03633110) | Genocea Biosciences, Inc. | 2018-08-29 |
| Effect of Mirtazapine Versus Placebo in Patients With Non-small Cell Lung Cancer and Anorexia (NCT04748523) | Instituto Nacional de Cancerologia de Mexico | 2018-08-29 |
| Phase Ib of L-NMMA and Pembrolizumab (NCT03236935) | The Methodist Hospital Research Institute | 2018-08-27 |
| Immune Checkpoint Inhibitors in Advanced Non-small Cell Lung Cancer and Discovery of New Biomarkers (NCT03658460) | Aalborg University Hospital | 2018-08-22 |
| Combinatory ImmunoTherapy-1 (Com-IT-1) Irradiation and PD-1 Blockade in Locally Advanced / Advanced NSCLC (NCT03644823) | Oslo University Hospital | 2018-08-15 |
| A Study of Atezolizumab in Patients With Unresectable, Locally Advanced or Metastatic NSCLC (J-TAIL) (NCT03645330) | Chugai Pharmaceutical | 2018-08-15 |
| QUILT-2.025 NANT Neoepitope Yeast Vaccine (YE-NEO-001): Adjuvant Immunotherapy Using a Personalized Neoepitope Yeast-Based Vaccine To Induce T-Cell Responses In Subjects W/ Previously Treated Cancers. (NCT03552718) | NantBioScience, Inc. | 2018-08-10 |
| A Study of Tiragolumab in Combination With Atezolizumab in Chemotherapy-Naïve Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NCT03563716) | Genentech, Inc. | 2018-08-10 |
| Methylprednisolone After Split-course Chemoradiotherapy For Bulky Local Advanced None-small Cell Lung Cancer (NCT03661567) | Sun Yat-sen University | 2018-08-09 |
| Study of Thymosin α1 to Reduce Acute Pneumonia For Bulky None-small Cell Lung Cancer (NCT03659578) | Sun Yat-sen University | 2018-08-09 |
| Consistency of PD-L1 Detecting Method Between E1L3N and 22C3 Monoclonal Antibodies in NSCLC Patients (NCT05129462) | Hunan Province Tumor Hospital | 2018-08-05 |
| Study of LYC-55716 With Pembrolizumab in Adult Subjects With Non-Small Cell Lung Cancer (NCT03396497) | Lycera Corp. | 2018-08-03 |
| Real World Study on First Line Crizotinib in ROS1 Rearranged Advanced Non-squamous Non-small Cell Lung Cancer (NCT03646994) | Hunan Province Tumor Hospital | 2018-08-01 |
| POINTING: Clinical Cohort Study of Patients With Melanoma and NSCLC Receiving Checkpoint Inhibitors (NCT04193956) | University Medical Center Groningen | 2018-08-01 |
| Atezolizumab Monotherapy and Consequent Therapy With Atezolizumab Plus Bevacizumab for NSCLC (NCT03616691) | Samsung Medical Center | 2018-08-01 |
| Study of Oral cMET Inhibitor INC280 in Chinese Patients With EGFR Wild-type Advanced Non-small Cell Lung Cancer (NSCLC) (NCT03240393) | Novartis Pharmaceuticals | 2018-07-31 |
| A Study of Tislelizumab in Combination With Chemotherapy Versus Chemotherapy in Advanced Lung Cancer (NCT03594747) | BeiGene | 2018-07-30 |
| A Study of Personalized Neoantigen Cancer Vaccines (NCT03794128) | Gritstone bio, Inc. | 2018-07-25 |
| A Study to Evaluate the Safety and Tolerability of Immunotherapy Combinations in Participants With Advanced Malignancies (NCT03629756) | Arcus Biosciences, Inc. | 2018-07-24 |
| A Study Evaluating the Efficacy and Safety of Tislelizumab Versus Chemotherapy in Advanced Non-Squamous Non-small Cell Lung Cancer (NCT03663205) | BeiGene | 2018-07-23 |
| Study to Evaluate CCS1477 in Advanced Tumours (NCT03568656) | CellCentric Ltd. | 2018-07-23 |
| A Study to Determine the Efficiency For Brain Metastasis NSCLC Patients Treated With Icotinib Alone or Combined With Radiation Therapy (NCT04058704) | Betta Pharmaceuticals Co., Ltd. | 2018-07-20 |
| Phase I/II Eval Safety & Prelim Activity Nivolumab Comb W/Vorolanib Pts W/Refractory Thoracic Tumors (NCT03583086) | Vanderbilt-Ingram Cancer Center | 2018-07-10 |
| A Trial of SHR-1210 (an Anti-PD-1 Inhibitor) in Combination With Hypofraction Radiotherapy in Patients With NSCLC (NCT03557411) | Shandong Cancer Hospital and Institute | 2018-07-09 |
| Exparel and Marcaine for Pain Management in Thoracoscopic Lobectomy Patients (NCT03682224) | Southern Illinois University | 2018-07-05 |
| Is Video-assisted Thoracoscopic Lobectomy a Clinical Alternative for Surgically Resectable Pathologic N2 NSCLC Patients (NCT03613467) | Tang-Du Hospital | 2018-07-04 |
| Clinical Trial to Evaluate the Safety and Effects of Ethnicity and Food on Pharmacokinetics of YH25448 (NCT03556436) | Yuhan Corporation | 2018-07-03 |
| [68Ga]-NeoBOMB1 Imaging in Patients With Malignancies Known to Overexpress Gastrin Releasing Peptide Receptor (GRPR) (NCT03724253) | Advanced Accelerator Applications | 2018-07-03 |
| REGN2810 (Anti-PD-1 Antibody), Platinum-based Doublet Chemotherapy, and Ipilimumab (Anti-CTLA-4 Antibody) Versus Pembrolizumab Monotherapy in Patients With Lung Cancer (NCT03515629) | Regeneron Pharmaceuticals | 2018-07-02 |
| A Study to Explore Treatment Regimens and Clinical Outcomes of the NSCLC Patients With Different Dirver Genes (NCT03710629) | The First Affiliated Hospital of Guangzhou Medical University | 2018-07-01 |
| 20K Distributed Learning Challenge (NCT03564457) | Maastricht Radiation Oncology | 2018-07-01 |
| High Dose Radiation Therapy With Concurrent Chemotherapy in Locally Advanced Non-small Cell Lung Cancer (NCT03598517) | Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine | 2018-07-01 |
| A Study Osimertinib in Patients With Stage 4 Non-small Cell Lung Cancer With Uncommon EGFR Mutations (NCT03434418) | Duke University | 2018-06-30 |
| NEUWAVE Flex Microwave Ablation System in the Ablation of Primary Soft Tissue Lesions of the Lung (NCT03603652) | Ethicon, Inc. | 2018-06-29 |
| Study of Pemetrexed + Platinum Chemotherapy With or Without Pembrolizumab (MK-3475) in Adults With Tyrosine Kinase Inhibitor- (TKI)-Resistant Epidermal Growth Factor Receptor- (EGFR)-Mutated Metastatic Non-squamous Non-small Cell Lung Cancer (NSCLC) (MK-3475-789/KEYNOTE-789) (NCT03515837) | Merck Sharp & Dohme LLC | 2018-06-29 |
| Identifying the Predictive Factors of Response to PD-1 or PD-L1 Antagonists (NCT03412058) | UNICANCER | 2018-06-27 |
| CAB-ROR2-ADC Safety and Efficacy Study in Patients With TNBC or Head & Neck Cancer (Ph1) and NSCLC or Melanoma (Ph2) (NCT03504488) | BioAtla, Inc. | 2018-06-27 |
| An Observational Study to Evaluate AZD9291 Treatment in Patients With T790M Positive Non-small Cell Lung Cancer (NCT03457220) | AstraZeneca | 2018-06-21 |
| Pembrolizumab and Itacitinib (INCB039110) for Non-Small Cell Lung Cancer (NCT03425006) | University of Pennsylvania | 2018-06-18 |
| PROCLAIM-CX-2029: A Trial to Find Safe and Active Doses of an Investigational Drug CX-2029 for Patients With Solid Tumors or DLBCL (NCT03543813) | CytomX Therapeutics | 2018-06-15 |
| Radiomics and Radiogenomics of Non-small Cell Lung Cancer (NCT06331975) | European Institute of Oncology | 2018-06-12 |
| APX005M With Nivolumab and Cabiralizumab in Advanced Melanoma, Non-small Cell Lung Cancer or Renal Cell Carcinoma (NCT03502330) | Yale University | 2018-06-09 |
| VMD-928 Monotherapy and in Combination With Pembrolizumab to Treat TrkA Overexpression Driven Solid Tumors or Lymphoma (NCT03556228) | VM Oncology, LLC | 2018-06-08 |
| Phase I Multicenter Trial Combining Nivolumab, Ipilimumab and Hypo-fractionated Radiotherapy for Pretreated Advanced Stage Non-small Cell Lung Cancer Patients (NCT03509584) | Assistance Publique Hopitaux De Marseille | 2018-06-07 |
| Real World Study on Erlotinib/Gefitinib Combined With Bevacizumab in Advanced Non-aquamous Non-small Cell Lung Cancer (NCT03647592) | Hunan Province Tumor Hospital | 2018-06-01 |
| Role of Circulating Tumor DNA (ctDNA) From LIquid Biopsy in Early Stage NSCLC Resected Lung Tumor Investigation (NCT03553550) | Addario Lung Cancer Medical Institute | 2018-06-01 |
| QUILT-2.024: Phase 2 Neoadjuvant, Consolidation, and Adjuvant Combination NANT Immunotherapy Versus Standard of Care in Subjects With Resectable Non-small Cell Lung Cancer (NCT03574649) | ImmunityBio, Inc. | 2018-06-01 |
| An Immuno-Therapy Study of Experimental Medication BMS-986205 Given With Nivolumab With or Without Chemotherapy Compared to Chemotherapy in Participants With Previously Untreated Stage IV or Recurrent Non-Small Cell Lung Cancer (NCT03417037) | Bristol-Myers Squibb | 2018-05-24 |
| Clinical Pharmacokinetics of TKIs in Chinese Patients of Hepatitis B (HBV) (NCT03680183) | Affiliated Cancer Hospital & Institute of Guangzhou Medical University | 2018-05-22 |